Corporate & Financial Press releases

Annual repport and Annual General Meeting of Shareholders

IPSOGEN to hold its Annual General Meeting of Shareholders on May 29, 2012, in Marseilles, France. Notice of Meeting of this Shareholders’ AGM published in the French official legal bulletin (“BALO”) is available here

Annual Report for 2011 is also available here in French only. An English translat...[more]

2011 annual results

Dynamic sales growth : +14% (+17% CER) with a 23% growth in kits revenues

Annual results impacted by non-recurring expenses and rationalization of IPSOGEN operations in the United States

Strong decrease of the operating cash burn

2012 launches: MN1 and NPM1 diagnostic kits[more]

Termination of the liquidity agreement

IPSOGEN (Alternext - FR0010626028, ISIN: FR0010626028) announces the termination on January 27, 2012 of the liquidity agreement entered into with PORTZAMPARC S.A.

More info[more]

Revenue for the year 2011: 9.50M€

A steady growth in consolidated revenue: +14% (17% at constant foreign exchange rate)

Confirmed success for the worldwide launch of the new test BCR-ABL IS MMR for leukemia

[more]

IPSOGEN acquires exclusive rights from PGDx for new biomarkers - mutations of the IDH1 and IDH2 genes - which play a role in brain cancers, acute myelogenous leukemia (AML) and other malignancies

IPSOGEN SA (Alternext: ALIPS), a majority-owned subsidiary of QIAGEN N.V. (Nasdaq: QGEN / Frankfurt, Prime Standard: QIA), today announced the acquisition of worldwide exclusive rights to testing for mutations of the IDH1 and IDH2 genes for diagnostic purposes from Personal Genome Diagnostics Inc, B...[more]

THE OFFER OF QIAGEN ON IPSOGEN WAS A SUCCESS

As announced by the AMF on November 29, 2011, QIAGEN holds, pursuant to its public offer on IPSOGEN, 89.30% of share capital and 86.47% of voting rights in IPSOGEN. This outcome is a tribute to the successful offer by QIAGEN, which provided IPSOGEN shareholders with an opportunity for a substantial ...[more]

Availability of the reply document established by IPSOGEN in response to a tender offer initiated by QIAGEN N.V.

This press release has been prepared and published by Ipsogen in accordance with Articles 231-27 3° and 231-28 of the General Regulations of the French stock market authority (Autorité des marchés financiers) (the “AMF”).[more]

Filing of a draft reply document established by IPSOGEN in response to a draft tender offer initiated by QIAGEN N.V.

This press release has been prepared and published by Ipsogen in accordance with Article 231-26 of the General Regulations of the French stock market authority (Autorité des marchés financiers) (the "AMF").[more]

Results for the first half of 2011

Sales growth: +17% (+21% at constant exchange rate)

High gross margin and an improved operating income

Satisfactory level of cash [more]

2011 First-half revenue

A steady growth in consolidated revenue: +17% (+21% at constant exchange rate)

Leukemia: successful launch of the BCR-ABL IS MMR assay

Breast cancer: development program in line with expected planning[more]